BDSX CEO Sells Shares to Cover Taxes on RSU Vesting
BIODESIX INC
Subscribe to track BDSX
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
BDSX CEO Sells Shares to Cover Taxes on RSU Vesting
Company: BIODESIX INC (BDSX) Form: 4 | Filed: 2025-11-13 Significance: Low
Insider: Hutton Scott Title: President & CEO | Relationship: Director, Officer
Transaction: • Type: Sell (to cover taxes) • Shares: 189 • Price: $7.62 • Value: $1,440 • Owned After: 37,311
Key Insight: The CEO automatically sold a small number of shares to cover tax liabilities from vesting Restricted Stock Units (RSUs). This is a routine, non-discretionary transaction with low market significance.
Market Context: The sale represents a negligible 0.0024% of the company's $60M market cap, indicating it is not a signal of the insider's sentiment towards the company's future.
Comprehensive Analysis
SEC Filing Analysis: BIODESIX INC (BDSX)
Executive Summary
- Trading Significance: Low
- Key Takeaway: The President & CEO of Biodesix conducted a minor, automatic "sell-to-cover" transaction to satisfy tax obligations arising from the vesting of Restricted Stock Units (RSUs).
- Market Impact: Neutral. The transaction is non-discretionary and its value is immaterial, suggesting no change in insider sentiment or expected market reaction.
Company Information
| Field | Value |
|---|---|
| Company | BIODESIX INC |
| Ticker Symbol | BDSX |
| CIK | 0001439725 |
| Industry | Medical Laboratories |
Insider Information
| Field | Value |
|---|---|
| Name | Hutton Scott |
| CIK | 0001697361 |
| Title/Position | President & CEO |
| Relationship | Director, Officer |
Transaction Details
This filing reports the vesting of 611 RSUs and a subsequent sale to cover taxes. The analysis focuses on the sale transaction.
| Field | Value |
|---|---|
| Form Type | 4 |
| Transaction Date | 2025-11-10 |
| Transaction Code | S (Sale) |
| Security Type | Common Stock |
| Shares Involved | 189 |
| Price Per Share | $7.62 |
| Total Value | $1,440.18 |
| Shares Owned After | 37,311 |
| Ownership Type | Direct |
Financial Impact Assessment
Transaction Materiality
| Metric | Value |
|---|---|
| Transaction Value | $1,440.18 |
| % of Market Cap | 0.0024% |
| Shares Transacted | 189 |
| % of Shares Outstanding | Not Available |
| Post-Transaction Ownership | 37,311 shares |
| Materiality Assessment | Low |
Impact Evaluation
- Market Cap Context: The transaction value of $1,440.18 is negligible compared to Biodesix's $60 million market capitalization. It falls far below the 0.1% threshold for even moderate significance.
- Transaction Significance: The sale is explicitly identified in the filing's footnotes as an automatic transaction to cover taxes upon RSU vesting. Such non-discretionary sales are common and do not reflect an insider's decision to reduce their stake in the company.
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: The transaction is a routine 'sell-to-cover' action, which is non-discretionary and carries no informational value regarding the insider's outlook on the company. The size of the sale is immaterial.
Volume & Sentiment
- Expected Volume Impact: Negligible. The transaction size is too small to impact trading volume.
- Sentiment Indicator: Neutral. The market typically disregards automatic tax-related sales.
Additional Context
Transaction Notes
- Special Circumstances: Footnote 4 explicitly states, "These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs." This confirms the non-discretionary nature of the sale. The sale was triggered by the vesting of 611 RSUs, which converted into common stock.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.
